DIAGNOSTIC VALUE OF CLINICAL AND BIOCHEMICAL, INSTRUMENTAL, IMMUNOGENETIC INDICES IN THE DEVELOPMENT OF COMORBID PATHOLOGY OF RESPIRATORY AND CARDIOVASCULAR SYSTEMS ACCORDING TO THE FACTOR ANALYSIS DATA

Abstract

184 patients suffering from chronic obstructive pulmonary disease (COPD) with co-existent arterial hypertension (AH) and 40 ppractically healthy persons have undergone factor analysis of 38 clinical and biochemical, instrumental, immunogenetic characteristics with the aim to create pathogenetic model of COPD with co-existent (AH).Results. The definition of factor loading for each index made it possible to identify three main factors. Factor I “combination of hypoxia, oxidative stress and inflammatory damage to bronchi” showed an important role of protein oxidation (PO) and lipid peroxidation (LP) in the development of COPD and AH. Factor II “interaction of ventilatory failure and hypoxia with cytokine-mediated inflammatory process, epigenetic modifications of cells in bronchoalveolar lavage (BAL) fluid” combined the indices of respiratory function, genetic markers, number of normal and pathological cells in BAL fluid, concentration of serum cytokines and BAL. Factor III “combination of immunocytogenetic status of the organism, respiratory function and PO” involved the indices of genome, concentration of interleukin-22, PO state, which are necessary for respiratory function.Conclusions. 1. The combination of COPD and AH aggravates dysfunction of cellular and humoral immunity, contributes to the progression of chronic inflammation. 2. The engagement of cell genome is the integral part of comorbid pathology mechanism, namely: chromosome morphology and DNA as well as epigenetic modifications of different somatic cells. 3. The study proved the genetic determinacy of intensity of functional disorders of respiratory and cardiovascular systems. 
PDF

References

Babych P.N., Hubenko A.V., Lapach S.N. The use of up-to-date statistics in the clinical trials experience. Third message. The odds ratio: concept, calculation, interpretation. Ukrainskyi medychnyi chasopys. 2005; 2(46): 113–119.

Belovol A.N., Kniazkova I.I., Tsyhankov A.I., Tolkacheva I.A. et al. Optimization of treatment of patients with chronic heart failure with co-existent chronic obstructive pulmonary disease. Ratsyonalnaya farmakoterapiya. 2014; 4(33): 52–57.

Horovenko N.H., Podolska S.V., Cherniuk N.V. The role of GSTT1 and GSTM1 gene polymorphism in the prognosis of the course of the disease (predisposition to COPD). Ukrainskyi pulmonolohichnyi zhurnal. 2009; 4: 45–49.

Bochkov N.P., Hinter Ye.K., Puzyrev V.P. Hereditary diseases: nationwide guidance. Moskwa. GEOTAR-Media. 2012; 936 p.

Puzyrev V.P. Genetic view on the phenomenon of combined diseases in man. Meditsinskaya genetika. 2008; 9: 3–9.

Surkova Ye.A., Kuzubova N.A., Ses T.P., Totolian A. Peculiarities of cytokine regulation in local and systemic inflammation in COPD. Med. immunologiya. 2010; 4–5(12): 349–354.

M. Cella, A . Fuchs, W. Vermi et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009; 457 (7230): 722–725.

J. Zidrik, E. Slaba, P. Joppa et al.Glutathione S-transferase and Microsomal Epoxide Hydrolase Gene polymorphism and risk of chronic obstructive pulmonary disease in Slovak Population. Croat. Med. J. 2008; 49: 182–191.

D.B. Hancock, M. Eijgelsheim, J.B. Wilk, S.A. Gharib et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet. 2010; 42: 45–52.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.